NCT03505944Unknown1 期
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Nordic Lymphoma Group17 个研究点 分布在 4 个国家目标入组 59 人开始时间: 2018年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 59
- 试验地点
- 17
- 主要终点
- Overall response rate
研究概览
简要总结
Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment
Experimental
Venetoclax+lenalidomide+rituximab
干预措施: Venetoclax (Drug)
结局指标
主要结局
Overall response rate
时间窗: 6 months
The primary objective is to assess the overall response rate (ORR) at 6 months with lenalidomide-venetoclax and rituximab, in patients with relapsed or refractory mantle cell lymphoma, by use of an MRD driven strategy. ORR includes complete (CR) and partial remissions (PR).
次要结局
未报告次要终点
研究者
研究点 (17)
Loading locations...
相似试验
招募中
2 期
Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaMarginal Zone LymphomaMZLLymphomaNCT06510309Gottfried von Keudell, MD PhD33
终止
2 期
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell LymphomaMantle Cell LymphomaNCT05025423Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins7
进行中（未招募）
1 期
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Follicular LymphomaRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Marginal Zone LymphomaNCT04447716Thomas Jefferson University4
撤回
2 期
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell LymphomaNCT06247540Northwestern University
进行中（未招募）
2 期
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaMarginal Zone LymphomaNCT04416451Memorial Sloan Kettering Cancer Center6